Recombinant IFNα2b improved immune response to hepatitis B vaccination in hemodialysis patients (Miquilena-Colina et al., 2009), indicating the safety profile of IFNα2b to patients with renal dysfunction. This evidence concerns the gene IFNA2 and hepatitis B virus infection.